Skip Ribbon Commands
Skip to main content

Prof Wong Tina

Assoc Prof Tina Wong from Singapore National Eye Centre

Prof Wong Tina

MBBS, FRCS(Ed), FRCOphth, FAMS, PhD (Lond)

Senior Consultant

Singapore National Eye Centre

Specialty: Glaucoma, Cataract & Comprehensive Ophthalmology

Sub-specialties: Glaucoma, Cataract & Comprehensive Ophthalmology

Conditions Treated by this Doctor:
Cataract, Glaucoma.

Clinical Appointments

  • Head & Senior Consultant Glaucoma Department Singapore National Eye CentreSingapore National Eye Centre
  • Senior Consultant Cataract & Comprehensive Ophthalmology Department Singapore National Eye CentreSingapore National Eye Centre

Academic Appointments

  • Professor SingHealth Duke-NUS Ophthalmology & Visual Sciences Academic Clinical Programme


Professor Tina Wong is the Head and Senior Consultant of the Glaucoma Department at Singapore National Eye Centre. Previously, she trained at the Moorfields Eye Hospital, London, UK. She combined her clinical training with academic research and was awarded the prestigious Wellcome Trust Vision Research Fellowship to pursue and complete a PhD at the Institute of Ophthalmology, University College London in Professor Sir Peng T. Khaw’ laboratory. The work of the thesis was in the area of matrix metalloproteinase and conjunctival wound healing in relation to post-operative scarring from glaucoma surgery. Her research lead to the award of the Founders Cup in the Oxford Ophthalmological Congress and the Moorfields Research Medal.
Professor Wong is also the head of the Ocular Therapeutics and Drug Delivery Research Group at the Singapore Eye Research Institute. She holds adjunct faculty appointments at the National University Hospital System (NUHS) and the School of Materials Science and Engineering at Nanyang Technological University, where she is also Director to the Ocular Therapeutic Engineering Centre (OTEC). 
Professor Wong’s research interests lie in wound repair and discovering novel drug targets as well as the innovative application of materials science and engineering to develop cutting edge solutions to improve on current medical and surgical treatments in glaucoma and other ophthalmic diseases. Professor Wong has published widely in these areas and has nationally funded research grants amounting to $8M. She holds 8 patents to her name and is a co-founder of a recent spin off biotech company originating from her research. This research also led to her being awarded the prestigious President’s Science and technology Award (Technology) in 2014. She is also the recipient of the MOH Clinician Scientist Award, the Asia Pacific Academy of Ophthalmology distinguished Service Award and the SingHealth GCEO Excellence Award.
Additionally, Professor Wong has presented at numerous international scientific and ophthalmological meetings and has also been invited as a speaker at international conferences as well as academic institutes and universities. She has supervised 4 PhD students from NTU, and medical students from Duke NUS Graduate medical school. 
She also serves on the Vision Save Philanthropy committee. Professor Wong is a member of the World Glaucoma Association, and examiner to the Royal College of Edinburgh of Surgeons (Ophthalmology), UK.


  • FRCOphth (2010)
  • FRCS(Ed) (2006)
  • PhD (Lond) (2003)
  • MBBS (1995)
  • BSc(Hons) (1992)

Professional Appointments and Committee Memberships

  • Adjunct Professor, Nanyang Technological University
  • Adjunct Associate Professor, Department of Ophthalmology, Yong Loo Lin School of Medicine, National University of Singapore
  • Executive Director, National Health and Innovation Centre, National Medical Research Council (2017 - present)
  • Member (Translational), Scientific Grant Review Committee, SingHealth Research Foundation (2014 - present)
  • Clinician-scientist Residents, SAB Scholarship Administration Panel Member, Ministry of Health (2014 - present)
  • Associate Advisory Board Member, World Glaucoma Association (2013 - present)
  • Examiner for Royal College of Surgeons of Edinburgh, (Ophthalmology) UK (2014 - present)


  • EXSA Clinical Service Award (Silver), Singapore National Eye Centre (2016)
  • Clinician Scientist Award (Senior Investigator), NMRC Singapore (2015)
  • President's Science and Technology Award (Technology) "Devices and nanomedicine for eye diseases" (2014)
  • Doug Johnson Memorial Lecture – Anti fibrosis International Congress on Glaucoma Surgery (2014)
  • Distinguished Service Award, Asia-Pacific Academy of Ophthalmology (2011)
  • Clinician Scientist Award, NMRC Singapore (2010)
  • Moorfields Eye Hospital Research Gold Medal, UK (2006)
  • Founders Cup, Oxford Ophthalmological Congress, UK (2006)
  • Wellcome Trust Research Fellowship, UK (2000)
  • Physiological Society Prize, St George's Hospital Medical School, London, UK (1992)

Research Interests

  • Pathophysiology of angle closure glaucoma

  • Wound healing and inflammation

  • Drug delivery for glaucoma

  • Glaucoma surgery and outcomes


  1. Inhibition of monocyte chemoattractant protein 1 prevent conjunctival fibrosis in an experimental model of glaucoma filtration surgery. Chong RS, Lee YS, Chu SWL, Toh LZ, Wong TTL. Invest Ophth Vis Sci. 2017 July;58(9)3432-39 (IF 3.3)

  2. Predicted patient demand for a new delivery system for glaucoma medicine. Ozdemir S, Wong TT, Allingham RR, Finkelstein EA. Medicine (Baltimore) 2017 April;96(5):e6626 (IF 1.803)

  3. Upregulation of distinct collagen transcripts in post-surgery scar tissue: a study of conjunctival fibrosis. Seet LF, Toh LZ, Chu SWL, Finger SN, Chua JLL, Wong TT. Disease Models and Mechanisms 2017 June:10(6):751-60 (IF 4.69)

  4. Sustained antibiotic-eluting intraocular lenses: A new Approach. Tan DW, Lim SG, Wong TT, Venkatraman SS. PLoS One 2016 Oct 11 (10):e0163857 (IF 4.41)

  5. Incidence and risk factors of elevated intraocular pressure following deep anterior lamellar keratoplasty. Huang OS, Mehta JS, Htoon HM, Tan DT, Wong TT. Am J Ophthalmology Aug 2016 (IF 3.87)

  6. Study on incentives for glaucoma medication adherence (SIGMA): study protocol for a randomised controlled trial to increase glaucoma medication adherence using value pricing. Bilger M, Wong TT, Kaye H, Lee J, Toh A, John G, Lamoureux E, Finkelstein E. Trials 2017 July 17:316 DOI: 10.1186/s13063-016-1459-1 (IF 1.73)

  7. Genome-wide association study identifies five new susceptibility loci for primary angle closure glaucoma. Nature Genetics April 2016 published online doi:10.1038/ng.3540 (IF 29.64)

  8. Valproic acid suppresses collagen by selective regulation of Smads in conjunctival fibrosis. See LF, Toh LZ, Finger SN, Chu SW, Stefanovic B, Wong TT J Mol Med Oct 2015 E Pub (IF 5.107)

  9. Anterior chamber angle and intraocular pressure changes after phacoemulsification: a comparison between eye with closed and open angle glaucoma. Siak ZJK, Quek D, Nongpuir M, Htoon HM, Amerasinghe N, Wong TT. J Glauc 2015 March (IF 2.1)

  10. How can nanoparticles be used to overcome the challenges of glaucoma treatment? Venkatraman SS, Wong T. Nanomedicine. 2014 Jul 9(9):1281-3 (IF 7.29)

  11. Evaluation of a prednisolone acetate-loaded subconjunctival implant for the treatment of recurrent uveitis in a rabbit model. Ang M, Ng X, Wong C, Yan P, Chee SP, Venkatraman SS, Wong TT. PLoS One. 2014 May 9(5):e97555 (IF 4.41)

  12. Layer by layer nanoparticles as an efficient siRNA delivery vehicle for SPARC silencing. Tan YF, Mundargi RC, Chen MHA, Lessig J, Neu B, Venkatraman SS, Wong TT. Small 2014 May 10(9):1790-8 (IF 8.37)

  13. Sustained drug release in nanomedicine: A long-acting nanocarrier based formulation for glaucoma. Natarajan JV, Darwitan A, Barathi VA, Ang M, Htoon HM, Boey F, Tham KC, Wong TT, Vekatraman SS. ACS Nano Jan 2014 8:419-29 (IF 12.88)

  14. Patient acceptance and attitude towards an alternate method of subconjunctival injection for the medical treatment of glaucoma. Chong RS, Su D, Tsai A, Jiang YZ, Htoon HM, Lamoureux EL, Aung T, Wong TT. J of Glaucoma, 2013, 22(3) 190-4. (IF 2.1)

  15. Efficacy and safety of collagen matrix implants in phacotrabeculectomy and comparison with mitomycin C augmented phacotrabeculectomy at 1 year. Narayaswamy A, Perera SA, Htoon HM, Hoh ST, Seah Sk, Wong TT, Aung T. Clin Exp Ophthalmol. 2013 41;552-60 (IF 2.35)

  16. A new design and application of bioelasters for better control of intraocular pressure in a glaucoma drainage device. Luong QM, Lei Shang, Ang M, Wong TT, Venkatraman SS. Adv Healthcare Materials 2013 July 9 EPub (5.797)

  17. A biodegradable sustained release Prednisolone acetate loaded microfilm drug delivery system effectively prolongs corneal allograft survival in the rat keratoplasty model. Liu YC, Peng Y, Lwing NC, Venkatraman SS, Wong TT, Mehta JS. PLoS One 2013 8(8):e70419 (IF 4.41)

  18. Novel insight into the inflammatory and cellular responses following experimental glaucoma surgery: a roadmap for inhibiting fibrosis. Seet LF, Finger SN, Chu SWL, Toh LZ, Wong TT. Current Mol Med 2013 13;911-28 (IF 4.48)

  19. Acceptance, attitudes and beliefs of Singaporean Chinese towards an ocular implant for glaucoma drug delivery. Foo R, Lamoureux E, Wong R, Ho SW, Chiang P, Rees G, Aung T, Wong TT. Invest Ophthal Vis Sci. 2012 Nov 27 E Pub (IF 3.4)

  20. Outcomes of trabeculectomy after Descemet stripping automated endothelial keratoplasty (DSAEK): a comparison with penetrating keratoplasty. Boey PY, Mehta JS, Ho CL, Tan DTH, Wong TT. Am J Ophthalmology. 2012;153:1091-8 (IF 3.87)

Research Trials

  • Novel Ocular Drug Delivery Systems

  • Sustained drug delivery of siRNA for post-operative scarring following glaucoma surgery

  • Ocular Wound Healing – cellular and molecular mechanisms in glaucoma surgery wound healing

  • A biodegradable valve for a new glaucoma drainage device with sustained drug releasing ability

  • The role of SPARC expression on conjunctival wound healing

  • Role of epigenetics in ocular surface wound healing

  • Role of tumour necrosis factor and mast cell chymase in bleb failure and conjunctival scarring following trabeculectomy